PUBLISHER: DelveInsight | PRODUCT CODE: 1105512
PUBLISHER: DelveInsight | PRODUCT CODE: 1105512
DelveInsight's, ''Uterine leiomyomata (Uterine Fibroids) - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Uterine leiomyomata (Uterine Fibroids) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Uterine leiomyomata (Uterine Fibroids) Understanding
Uterine leiomyomata or fibroids are an extremely common benign neoplasm in women of reproductive age. Although they are benign, they can have a significant impact on the everyday physical and mental well-being of women with this condition. Fibroids originate from uterine smooth muscle cells (myometrium) whose growth is primarily dependent on the levels of circulating estrogen. Further information regarding the pathogenesis of fibroids is poorly understood. Fibroids can either present as an asymptomatic incidental finding on imaging, or symptomatically. Common symptoms include abnormal uterine bleeding, pelvic pain, disruption of surrounding pelvic structures (bowel and bladder), and back pain. Uterine fibroids typically are seen in three significant locations: subserosal (outside the uterus), intramural (inside the myometrium), and submucosal (Inside the uterine cavity). They can further be broken down to pedunculated or not..
"Uterine leiomyomata (Uterine Fibroids) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Uterine leiomyomata (Uterine Fibroids) pipeline landscape is provided which includes the disease overview and Uterine leiomyomata (Uterine Fibroids) treatment guidelines. The assessment part of the report embraces, in depth Uterine leiomyomata (Uterine Fibroids) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uterine leiomyomata (Uterine Fibroids) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Uterine leiomyomata (Uterine Fibroids) Emerging Drugs
Fezolinetant: Ogeda
Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women's health disorders. Fezolinetant's mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women.
Further product details are provided in the report……..
Uterine leiomyomata (Uterine Fibroids) : Therapeutic Assessment
This segment of the report provides insights about the Uterine leiomyomata (Uterine Fibroids) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies Uterine leiomyomata (Uterine Fibroids). The companies which have their Uterine leiomyomata (Uterine Fibroids) drug candidates in the most advanced stage, i.e phase II include Ogeda
DelveInsight's report covers around 10+ products under different phases of clinical development like
Uterine leiomyomata (Uterine Fibroids) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Uterine leiomyomata (Uterine Fibroids) : Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uterine leiomyomata (Uterine Fibroids) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uterine leiomyomata (Uterine Fibroids) drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Uterine leiomyomata (Uterine Fibroids) : Overview
Pipeline Therapeutics
Therapeutic Assessment
Uterine leiomyomata (Uterine Fibroids) - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Vilaprisan: Bayer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Fezolinetant: Ogeda
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical Stage Products
CFI 400945: Contex Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Uterine leiomyomata (Uterine Fibroids) Key Companies
Uterine leiomyomata (Uterine Fibroids) Key Products
Uterine leiomyomata (Uterine Fibroids) - Unmet Needs
Uterine leiomyomata (Uterine Fibroids) - Market Drivers and Barriers
Uterine leiomyomata (Uterine Fibroids) - Future Perspectives and Conclusion
Uterine leiomyomata (Uterine Fibroids) Analyst Views
Uterine leiomyomata (Uterine Fibroids) Key Companies
Appendix